Citation
Weisblum, Yiska, et al. "Escape From Neutralizing Antibodies By SARS-CoV-2 Spike Protein Variants." ELife, vol. 9, 2020.
Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020;9.
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H. H., Michailidis, E., Gaebler, C., Agudelo, M., Cho, A., Wang, Z., Gazumyan, A., Cipolla, M., Luchsinger, L., Hillyer, C. D., Caskey, M., ... Bieniasz, P. D. (2020). Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. ELife, 9. https://doi.org/10.7554/eLife.61312
Weisblum Y, et al. Escape From Neutralizing Antibodies By SARS-CoV-2 Spike Protein Variants. Elife. 2020 10 28;9 PubMed PMID: 33112236.
TY - JOUR
T1 - Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
AU - Weisblum,Yiska,
AU - Schmidt,Fabian,
AU - Zhang,Fengwen,
AU - DaSilva,Justin,
AU - Poston,Daniel,
AU - Lorenzi,Julio Cc,
AU - Muecksch,Frauke,
AU - Rutkowska,Magdalena,
AU - Hoffmann,Hans-Heinrich,
AU - Michailidis,Eleftherios,
AU - Gaebler,Christian,
AU - Agudelo,Marianna,
AU - Cho,Alice,
AU - Wang,Zijun,
AU - Gazumyan,Anna,
AU - Cipolla,Melissa,
AU - Luchsinger,Larry,
AU - Hillyer,Christopher D,
AU - Caskey,Marina,
AU - Robbiani,Davide F,
AU - Rice,Charles M,
AU - Nussenzweig,Michel C,
AU - Hatziioannou,Theodora,
AU - Bieniasz,Paul D,
Y1 - 2020/10/28/
PY - 2020/07/22/received
PY - 2020/10/27/accepted
PY - 2020/10/29/pubmed
PY - 2020/12/19/medline
PY - 2020/10/28/entrez
KW - COVID19
KW - SARS-CoV-2
KW - VSV
KW - antibody
KW - immunology
KW - infectious disease
KW - inflammation
KW - microbiology
KW - virus
JF - eLife
JO - Elife
VL - 9
N2 - Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric VSV/SARS-CoV-2 reporter virus, we show that functional SARS-CoV-2 S protein variants with mutations in the receptor-binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Notably, SARS-CoV-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequencies in circulating SARS-CoV-2 populations. Finally, the emergence of antibody-resistant SARS-CoV-2 variants that might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of antibody combinations that target distinct neutralizing epitopes.
SN - 2050-084X
UR - https://www.unboundmedicine.com/medline/citation/33112236/Escape_from_neutralizing_antibodies_by_SARS_CoV_2_spike_protein_variants_
DB - PRIME
DP - Unbound Medicine
ER -